There are approximately 25 million Americans living with Demodex Blepharitis (DB), which accounts for 58% of eye care patients in the U.S. Additionally, 2/3 of Blepharitis cases are associated with Demodex mites. Over the last decade, our practice offered multiple effective ways to manage demodex blepharitis including office-based procedures such as BlephEx, ZEST, OptiLight IPL, LLLT as well as at-home therapies with gentle eyelid cleansers (ie Tea Tree Oil wipes/foams/gels and Avenova HOCL eyelid spray). However, as of September 2023, there's another player and it just became available as a pharmaceutical option, Xdemvy.
Xdemvy is the first and only FDA-approved topical drop indicated for the treatment of Demodex Blepharitis. Lotilaner, the active ingredient in Xdemvy, is a lipophilic agent in an aqueous drop that acts specifically via mite GABA-gated chloride channels to target, paralyze, and kill Demodex mites.
In just 6 weeks & twice daily use, collarettes are reduced, mites are eradicated, and erythema is gone.
90% of patients reported the drop as neutral to very comfortable. No contraindication notes.
Visit your eye care specialist to learn more about DB and if Xdemvy is right for you.
Adverse Reaction with Xdemvy: the most common adverse reaction was stinging/burning upon instillation in 10% of patients and less than 2% of patients reported hordeolum/chalazion and punctate keratitis.
Click here to learn more about other advanced dry eye treatment options.
#xdemvy #demodex #blepharitis #mites #tarsus #fda #beverlyhills #LasVegas #visionexpo #kol